Artificial Intelligence in Lung Cancer: Opening New Avenues for Detection, Diagnosis, and Prognostication
By Mizuki Nishino, MD, MPH Posted: April 16, 2020 Dr. Mizuki Nishino Artificial intelligence (AI) approaches have emerged as promising tools to address important unmet needs across different specialties in […] Read more
By Corey J. Langer, MD, ILCN Editor Posted: April 16, 2020 Dr. Corey Langer Michele Carbone MD, Ph.D and colleagues have penned a far-ranging editorial, now published online in the […] Read more
Increasing the Role of Local Consolidation in Oncogenic-Driven Advanced NSCLC
By Youquan Li, MD, FRCR, and Andrea Bezjak, MDCM, MSc, FRCPC Posted: February 12, 2020 Targeted agents including TKIs of EGFR, ALK, and ROS1 have significantly improved the outcomes of […] Read more
Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia
Posted: February 12, 2020 Ravi Salgia, MD, PhD, is the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and the associate director for clinical sciences at City of Hope’s […] Read more
By Alexander Drilon, MD Posted: February 12, 2020 The receptor tyrosine kinases TRKA/B/C are encoded by the genes NTRK1/2/3. TRK fusions are oncogenic drivers of various adult and pediatric cancers. […] Read more
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: A Q&A With Dr. Edgardo S. Santos Castillero
Posted: February 12, 2020 Edgardo S. Santos Castillero, MD, FACP, is an IASLC Lung Cancer News Editorial Group Member and served as a co-chair on the expert panel that developed […] Read more
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC
By Neal Ready, MD, PhD Posted: February 12, 2020 Dr. Neal Ready Programmed death receptor (PD-1) checkpoint monoclonal antibody therapy has proven a major advancement in the management of advanced […] Read more
Posted: February 12, 2020 November 1, 2019—After years of political volleying and public outcry, Austria implemented a full indoor smoking ban in bars, cafes, and restaurants. With its capitol, Vienna, […] Read more
Novel Insights on ctDNA Dynamics During Targeted Therapy and Immune Checkpoint Blockage in NSCLC
By Christian Rolfo, MD, PhD, MBA, Dr.h.c. Posted: December 11, 2019 IN REFERENCE TO: Phallen J, Leal A, Woodward BD, et al. Early Noninvasive Detection of Response to Targeted Therapy […] Read more
Lung Cancer Leading the Charge for Tumor-Agnostic Targeted Therapies
By Robert C. Doebele, MD, PhD Posted: December 11, 2019 Dr. Robert C. Doebele Early in the drug development of targeted therapies, specific oncogene mutations were often associated with a […] Read more